In order for providers to achieve balance between patients who want more direction and patients who want more autonomy, the healthcare industry must first find some measure of patient engagement, said Julia Adler-Milstein, PhD, assistant professor at the School of Information and the School of Public Health at the University of Michigan.
In order for providers to achieve balance between patients who want more direction and patients who want more autonomy, the healthcare industry must first find some measure of patient engagement, said Julia Adler-Milstein, PhD, assistant professor at the School of Information and the School of Public Health at the University of Michigan.
Transcript (modified)
How do providers reconcile between patients who want to be told what to do and patients who want more of a say in their care?
The first thing we need to do is really figure out how do we measure patient engagement. And those measures, I think, need to be subjective because people are going to have different definitions of what it means for them to be engaged.
But right now we haven’t even had the ability to measure that well, and so we don’t know where we stand today. A lot of healthcare systems will say “I’m doing patient engagement” and then you ask them what they’re doing and they say, “Oh, you know, I have a portal where a patient can look up their lab results." And, again, maybe for some patients that feels like they are engaged, but for other patients that probably is going to really fall short of how they want to be engaged.
But until we measure it, it’s going to be very hard to know how we’re doing, and it’s going to be very hard to ultimately tie incentives to it. I think this is going to be the really transformative piece of this, when healthcare delivery systems feel like they have to prioritize patient engagement if they want to be competitive and effective; but I think patient engagement has just not reached that level of prioritization to date.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More